• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·Brazil·Technology·NGRD3.SA
Share

Neogrid Participacoes S.A. Stocks

R$ 34.28Last Updated 14.07.2026

Issuer Rating

3/7
Performance

Average

Risk

High

Recommendation

Sell

Market Cap

R$ 59.75M

R$ 34.28
Key Takeaways

Risk factor

Very high price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Very low or no dividends

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Neogrid Participações S.A., operating with its subsidiaries, delivers tailor-made software solutions globally to facilitate the comprehensive management and alignment of supply chains. Their services include the development, licensing, distribution, and deployment of these custom platforms. Additionally, the company provides specialized technical consulting and instructional programs. Its service portfolio further extends to essential functions such as software and database installation, system configuration, ongoing maintenance, and critical IT support. Neogrid serves a broad spectrum of clients, including manufacturers and retail businesses, alongside specific sectors like agribusiness, consumer packaged goods (CPG), electronics, fashion, home renovation, and the pharmaceutical and healthcare industries. Established in 1999, the firm's headquarters are situated in Joinville, Brazil.

Company Valuation

Fairly valued
4/7

Based on key historical and expected multiples, the stock is fairly valued relative to its peers. In particular, the stock is underpriced on P/E, of fair value on EV/EBIT

Data is available to registered users only
Sign up to access detailed valuation

Target Price

Slightly negative
3/7

The average target price of NGRD3.SA is 30.0 and suggests 12.5% downside potential. Usually, this means a SELL recommendation among investment firms, or a recommendation

Data is available to registered users only
Sign up to access analyst forecasts

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

02.11.2026 17:42

One of the boldest bets: Marvell will acquire optics developer Lumentum for $115 billion

02.11.2026 17:30

Shares of biotech company Inovio soared 240% following the drug's approval. Is there still upside potential?

02.11.2026 17:08

"Hope for a Breakthrough in the Iran Stalemate": Oil Prices Plunge 4%

02.11.2026 16:18

Morning in New York: The High-Tech Sector Cools Off Ahead of the Election

02.11.2026 16:04

"I know he's an idiot": Ryanair CEO assesses the business benefits of his feud with Musk

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026